Overview

A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Tolerability of Exenatide in Adolescent Subjects With Type 2 Diabetes Mellitus

Status:
Completed

Trial end date:
2007-02-01

Target enrollment:

Participant gender:

Summary

This study will be the first evaluation of exenatide in adolescent subjects with type 2 diabetes mellitus and is designed to evaluate the blood levels of the drug (pharmacokinetics), the drug's biochemical and physiological effects (pharmacodynamics), and tolerability of exenatide in these subjects.

Phase:

Phase 2

Details

Lead Sponsor:

AstraZeneca

Collaborator:

Eli Lilly and Company

Treatments:

Exenatide